Cocrystal pharma, inc. (COCP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net income (loss)

-53,130

-48,169

-44,610

-44,695

-44,524

-49,048

435

41

382

-613

-71,564

-71,186

-73,410

-74,874

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,305

-8,706

-9,090

-5,457

0

0

0

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Bad debt expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

401

360

328

326

0

0

0

Depreciation and amortization expense

105

98

79

66

58

50

64

78

90

101

119

144

171

201

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

138

520

603

570

531

0

0

0

Amortization of right of use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

425

351

483

496

490

562

537

558

507

614

660

-620

41

548

1,182

3,059

3,560

2,934

2,062

1,329

120

38

37

44

48

55

0

0

0

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

58

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on operating lease liabilities

150

133

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred income tax

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liabilities in excess of proceeds from financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Amortization of financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36

182

164

155

160

0

0

0

Change in fair value of derivative liabilities

129

256

69

165

385

306

696

419

357

907

1,051

1,161

1,901

2,603

0

0

0

-

-

-

-

-

-

-

-

-

-

-302

-264

153

196

174

136

-281

0

0

0

Gain on settlement of mortgage note receivable

-

-

-

-

-

106

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liabilities in excess of proceeds from financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense related to warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Equity interest in subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,181

5,500

5,073

4,116

758

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-

644

0

0

0

-

-

-

-

-

-

-

-16

-11

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

445

39

31

560

0

0

0

Inventories

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-174

-975

-157

-665

0

0

0

Prepaid expenses and other current assets

33

-22

-77

-134

-34

86

37

53

-49

-413

-385

-19

-177

76

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-436

-467

-340

-102

0

0

0

Deposits

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

445

919

712

596

401

240

84

-321

-304

281

-342

-421

-1,963

-2,022

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on mortgage note receivable

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

10

17

25

28

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Deferred taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,660

172

476

652

0

0

0

Accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-80

54

696

680

1,047

0

0

0

Net cash used in operating activities - continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,722

-2,016

-1,608

-1,894

-420

0

0

0

Net cash (used in) provided by operating activities

-5,769

-1,563

-2,303

-3,129

-4,194

-8,290

-7,900

-7,937

-6,929

-6,903

-7,624

-8,584

-12,665

-14,655

-15,394

-15,435

-12,800

-10,317

-9,032

-6,984

-5,791

-6,012

-5,065

-4,874

-4,514

-3,686

0

0

0

-

-

-

-

-

-

-

-

Investing activities:
Cash acquired in acquisition of Biozone Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

589

0

0

0

-

-

-

-

-

-

-

0

-

-

-

-

Purchases of property and equipment

213

145

159

52

48

28

13

5

12

40

42

55

66

51

171

357

352

339

218

23

10

5

0

0

0

-

-

-

-

152

737

843

792

575

0

0

0

Capital expenditures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Cash acquired in reverse merger with Biozone Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Long-term deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

12

13

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from settlement of mortgage note receivable

-

-

-

-

-

1,400

1,400

1,400

1,400

0

0

0

0

-

-

-

-

0

47

37

19

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments received on mortgage note receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-21

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-213

-145

-159

-52

-48

1,372

1,399

1,407

1,388

-40

-17

4

-31

3

-132

-334

-275

-262

2,556

2,750

5,520

6,082

3,361

3,347

572

-4

166

125

90

-152

-737

-843

-207

10

0

0

0

Financing activities:
Payments on finance lease liabilities

219

214

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Borrowings from noteholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Repayment of borrowings from noteholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,650

5,275

4,900

4,807

2,725

0

0

0

Payment of deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

150

0

0

0

Proceeds from sale of common stock, net of transaction costs

0

-

-

0

0

-

-

-

-

-

-

-

-

9,013

9,013

5,004

9,054

15,862

0

0

0

-

0

0

0

-

0

0

0

650

1,355

1,355

1,355

705

0

0

0

Proceeds from issuance of convertible notes

-

-

-

-

-

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,750

4,250

4,250

3,800

2,750

0

0

0

Proceeds from issuance of notes payable

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series A preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and options to Teva, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

228

185

265

264

80

80

0

0

3

6

6

6

23

21

79

117

116

117

59

22

7

0

0

0

-

-

-

-

-

-

-

-

Payment to shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

19,097

6,424

3,793

3,835

11,585

8,893

9,869

9,949

5,264

4,080

3,080

7,009

4,009

9,016

9,019

5,010

9,060

15,885

15,883

15,941

11,929

2,866

2,867

2,809

2,772

7

95

-354

-120

1,713

2,055

786

-61

575

0

0

0

Net increase in cash and restricted cash

13,115

4,716

1,331

654

7,343

1,975

3,368

3,419

-277

-2,863

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES:
Recognition of operating lease right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842, Leases

-

833

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-4,015

-

9,407

11,707

11,658

2,936

1,163

1,282

-1,170

-3,683

-2,567

-1,710

-635

-27

-699

-1,665

-2,162

164

0

0

0

Unrealized loss on marketable securities net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cashless exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

35

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain (loss) on marketable securities net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Estimated fair value of warrants exchanged for common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cashless exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

256

531

577

655

539

0

0

0